Peel Hunt Reiterates “Buy” Rating for Oxford BioMedica (OXB)

Peel Hunt reaffirmed their buy rating on shares of Oxford BioMedica (LON:OXB) in a research report released on Tuesday morning.

Shares of LON:OXB opened at GBX 722 ($9.43) on Tuesday. Oxford BioMedica has a 12-month low of GBX 4.44 ($0.06) and a 12-month high of GBX 13.19 ($0.17).

In other news, insider Lorenzo Tallarigo acquired 291 shares of Oxford BioMedica stock in a transaction dated Monday, September 24th. The stock was bought at an average price of GBX 913 ($11.93) per share, for a total transaction of £2,656.83 ($3,471.62). In the last 90 days, insiders have bought 1,050 shares of company stock valued at $797,369.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Featured Story: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with's FREE daily email newsletter.

Leave a Reply